What You Will Learn

Please join Carterra at our upcoming symposium in Munich, Germany. You will spend the day learning about high-throughput drug discovery and antibody therapeutics with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Antibody discovery in 90 days! Screening, identification & characterization
New methods in DELs, PROTACs and other formats
New technology and innovations during the pandemic
Data analysis routines & automation
Best practices in analyzing SPR data

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Agenda

08:45 – 09:00	Arrive and Check-in
09:00 – 09:30	Networking and Coffee/Tea
09:30 – 09:45	Symposium Begins—Welcome
09:45 – 10:30	Kate Hastie, PhD, Instructor, Ollmann Saphire Lab, La Jolla Institute for Immunology Keynote Address—From Alpha to Omicron: A global consortium study to identify broadly reactive SARS-CoV2 therapeutic antibodies
	Abstract: The Coronavirus Immunotherapeutic Consortium (CoVIC) was formed to develop prevention and therapeutic strategies against SARS-CoV-2 that could be mobilized in low- and middle-income countries. With now almost 400 unique antibodies, CoVIC has mapped the epitope landscape on the SARS-CoV-2 Spike protein using the Carterra LSA platform. This information, coupled with high throughput viral neutralization screens and in vivo protection studies, has revealed key communities of receptor-binding domain (RBD)-targeted antibodies that are resistant to major emerging variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
10:30 – 11:00	Randi Westh Hansen, PhD, Senior Scientist, Antibody Technology, Symphogen a Servier Company Characterizing antibody libraries by high throughput Surface Plasmon Resonance – from haystack to lead
	Abstract: Using high-throughput Surface Plasmon Resonance (HTP SPR) it is possible to measure hundreds of binding interactions in parallel in a real-time and label-free manner. Binding kinetics, affinities, and cross-reactivity to orthologs or protein family members of large antibody panels combined with epitope binning enable rapid characterization of hundreds of antibody-antigen interactions and epitope coverage. In my presentation, I will show examples of how we use HTP SPR in our workflow of characterizing therapeutic monoclonal antibodies and how HTP SPR combined with a mutagenesis approach was used to identify the epitopes of a two-mAb mixture binding CD40.
11:00 – 11:30	Break and Networking
11:30 – 12:00	Marina Roell, PhD, Principal Scientist, Alector MerTK Agonism and Antagonism: Patterns Revealed by Domain Binding Studies using High Throughput Parallel SPR Analysis on the Carterra LSA
	Abstract: Mer Tyrosine Kinase (MerTK) has been implicated in several diseases and is a potential target for therapeutic antibodies. Different diseases may benefit from either increasing or decreasing MerTK activity. We used Carterra's LSA and analysis software to evaluate the epitope diversity of a panel of anti-MerTK antibodies by traditional competitive binning and by comparing IgG binding to domain-swapped chimera of MerTK extracellular domain constructs. Differential modulation of biological activity appears to be mediated by antibodies specific to epitopes in different domains of MerTK. These results enabled identification of binding regions for the epitope bins and investigation of the correlation between domain binding and differential activities of anti-MerTK IgGs.
12:00 – 13:00	Lunch and Networking - Cantina
13:00 – 13:30	Lawrence Kerr, Senior Scientist, GSK Will be announced once their legal team has given approval for the presentation
	Abstract: TBD
13:30 – 14:00	Jon Popplewell, PhD, Field Applications Scientist, Carterra New Applications Using HT-SPR Technology
	Abstract: From kinetics to epitope characterization, HT-SPR has become an indispensable technology for the characterization of biotherapeutics. This presentation will focus on recently developed assays that expand the versatility of HT-SPR in the biotherapeutic space as well as move into new areas drug discovery. Topics include potency-based assays in addition to approaches focused on characterization of small molecule formats including targeted protein degraders (TPDs) and DNA encoded libraries (DELs).
14:00 – 14:30	Break and Networking
14:30 – 15:00	Judicaël Parisot, PhD, Senior Field Applications Scientist, Carterra Best Practices for Designing and Analyzing Epitope Binning Experiments Using the Carterra LSA and Epitope Software
	Abstract: We will describe practical guidelines for designing, executing and analyzing epitope binning assays using Carterra’s LSA and industry-leading Epitope™ software. We will provide tips and tricks for leveraging the power of our software to groom a data set, remove unnecessary complexity, and apply community analysis while retaining sufficient nuance to most accurately describe the epitope landscape.
15:00 – 15:30	Oliver Zaccheo,, PhD, Senior Group Leader, SPR and Biophysical Assays, UCB Will be announced once their legal team has given approval for the presentation
	Abstract: TBD
15:30 – 16:00	Networking and 100th LSA Celebration
16:00	Symposium Ends

What You Will Learn

Register Here

Agenda